Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Metastatic Neoplasm”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT04994795
What this trial is testing

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Sophia Genetics SAS 4,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT04395677
What this trial is testing

AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 173
Not applicableUnknownNCT01754272
What this trial is testing

A Non-Interventional Follow-Up to the VELOUR Study - Translational Research

Who this might be right for
Metastatic Colorectal Cancer
KU Leuven 1,226
Early research (Phase 1)Study completedNCT00004604
What this trial is testing

Biological Therapy in Treating Patients With Metastatic Cancer

Who this might be right for
Breast CancerColorectal CancerExtrahepatic Bile Duct Cancer+9 more
Duke University 24
Testing effectiveness (Phase 2)Ended earlyNCT00373204
What this trial is testing

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Who this might be right for
Lung Cancer
Pharmacyclics LLC. 50
Large-scale testing (Phase 3)Not Yet RecruitingNCT07464327
What this trial is testing

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Who this might be right for
Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company 450
Not applicableWithdrawnNCT01936961
What this trial is testing

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors

Who this might be right for
Metastatic Non-Small Cell Lung CancerMetastatic Colon CancerMetastatic Triple Negative Breast Cancer
Western Regional Medical Center
Large-scale testing (Phase 3)Not Yet RecruitingNCT07633873
What this trial is testing

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 500
Testing effectiveness (Phase 2)Ended earlyNCT01126866
What this trial is testing

Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy

Who this might be right for
Colorectal Carcinoma
National Center for Tumor Diseases, Heidelberg 35
Not applicableNot Yet RecruitingNCT06725537
What this trial is testing

Comprehensive Demographics and Clinical Profile of NSCLC Patients

Who this might be right for
Lung Cancer Non Small Cell
D'Or Institute for Research and Education 500
Not applicableLooking for participantsNCT03545256
What this trial is testing

Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)

Who this might be right for
Cancer T1-N0 or T2-N0 of the Oral Cavity
University Hospital, Montpellier 25
Large-scale testing (Phase 3)Ended earlyNCT03850795
What this trial is testing

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Hinova Pharmaceuticals USA, Inc. 104
Early research (Phase 1)Active Not RecruitingNCT03589339
What this trial is testing

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Who this might be right for
RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more
Nanobiotix 145
Testing effectiveness (Phase 2)Looking for participantsNCT07066995
What this trial is testing

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

Who this might be right for
Pancreatic CancerPancreatic CarcinomaPancreatic Cancer Non-resectable+1 more
Essen Biotech 60
Early research (Phase 1)Study completedNCT02870010
What this trial is testing

Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres

Who this might be right for
Localized Non-Resectable Adult Hepatocellular Carcinoma
Centre Hospitalier Universitaire Dijon 21
Testing effectiveness (Phase 2)Ended earlyNCT00109850
What this trial is testing

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Who this might be right for
Esophageal Cancer
SWOG Cancer Research Network 22
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Large-scale testing (Phase 3)Study completedNCT00349102
What this trial is testing

Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-small-cell Lung
Centre Leon Berard 242
Testing effectiveness (Phase 2)Study completedNCT04623775
What this trial is testing

Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
Bristol-Myers Squibb 468
Large-scale testing (Phase 3)Study completedNCT02713867
What this trial is testing

A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Who this might be right for
Lung Cancer
Bristol-Myers Squibb 363
Next Page